

SNMMI NEWSLINE

- 13N** *JNM* Editors' Choice Awards for 2021
- 13N** Outstanding *JNMT* Articles for 2021
- 14N** SNMMI Leadership Update: Putting Patients First: A Year in Review
Richard L. Wahl
- 15N** SNMMI Procedure Standard/EANM Practice Guideline for Nuclear Medicine Evaluation and Therapy of Differentiated Thyroid Cancer: Abbreviated Version
Anca M. Avram, Luca Giovanella, Bennett Greenspan, Susan A. Lawson, Markus Luster, Douglas Van Nostrand, Justin G. Peacock, Petra Petranović Ovcariček, Edward Silberstein, Mark Tulchinsky, et al.

EDITOR'S PAGE

- 805** How Many Theranostics Centers Will We Need in the United States?
Johannes Czernin and Jeremie Calais

COMMENTARY

- 807** A Letter from Ukraine
Ken Herrmann and Kmetyuk Yaroslav

DISCUSSIONS WITH LEADERS

- 808** Precision Medicine Clinical Trials: A Conversation Between Peter O'Dwyer and Lale Kostakoglu
Peter J. O'Dwyer and Lale Kostakoglu

ISSUES AND CONTROVERSIES

- 812** The VISION Forward: Recognition and Implication of PSMA-¹⁸F-FDG+ mCRPC
Hossein Jadvar

EDITORIAL

- 816** Why We Did What We Did: PSMA PET/CT Selection Criteria for the VISION Trial
Phillip H. Kuo, Taylor Benson, Richard Messmann, and Michael Groaning

THE STATE OF THE ART

- 819** The Importance of Training, Accreditation, and Guidelines for the Practice of Theranostics: The Australian Perspective
Sze Ting Lee, Louise M. Emmett, David A. Pattison, Michael S. Hofman, Dale L. Bailey, Melissa J. Latter, Roslyn J. Francis, and Andrew M. Scott

CONTINUING EDUCATION

- 823** Prostate Cancer Treatment: ¹⁷⁷Lu-PSMA-617 Considerations, Concepts, and Limitations
Oliver Sartor and Ken Herrmann

HOT TOPICS

- 830** Tau Beats Amyloid in Predicting Brain Atrophy in Alzheimer Disease: Implications for Prognosis and Clinical Trials
Maura Malpetti, Renaud La Joie, and Gil D. Rabinovici

THERANOSTICS

Clinical

- 833** Pretherapeutic Comparative Dosimetry of ¹⁷⁷Lu-rhPSMA-7.3 and ¹⁷⁷Lu-PSMA I&T in Patients with Metastatic Castration-Resistant Prostate Cancer
Benedikt Feurecker, Maythinee Chantadisaï, Anne Allmann, Robert Tauber, Jakob Allmann, Lisa Steinhelfer, Isabel Rauscher, Alexander Wurzer, Hans-Jürgen Wester, Wolfgang A. Weber, et al.
- 840** Effects of ²²⁵Ac-Labeled Prostate-Specific Membrane Antigen Radioligand Therapy in Metastatic Castration-Resistant Prostate Cancer: A Meta-Analysis
Dong Yun Lee and Yong-il Kim
- 847** ■ **FEATURED ARTICLE OF THE MONTH.** Head-to-Head Comparison of ⁶⁸Ga-PSMA-11 PET/CT and mpMRI with a Histopathology Gold Standard in the Detection, Intraprostatic Localization, and Determination of Local Extension of Primary Prostate Cancer: Results from a Prospective Single-Center Imaging Trial
Ida Sonni, Ely R. Felker, Andrew T. Lenis, Anthony E. Sisk, Shadfar Bahri, Martin Allen-Auerbach, Wesley R. Armstrong, Voraparee Suvannareg, Teeravut Tubtawee, Tristan Grogan, et al.
- 855** ■ **SPECIAL CONTRIBUTION.** ¹⁸F-DCFPyL PET Acquisition, Interpretation, and Reporting: Suggestions After Food and Drug Administration Approval
Hong Song, Andrei Iagaru, and Steven P. Rowe

Translational

- 860** ■ **INVITED PERSPECTIVE.** PET with a ⁶⁸Ga-Labeled FAPI Dimer: Moving Toward Theranostics
Muhsin H. Younis, Xiaoli Lan, and Weibo Cai
- 862** Synthesis, Preclinical Evaluation, and a Pilot Clinical PET Imaging Study of ⁶⁸Ga-Labeled FAPI Dimer
Liang Zhao, Bo Niu, Jianyang Fang, Yizhen Pang, Siyang Li, Chengrong Xie, Long Sun, Xianzhong Zhang, Zhide Guo, Qin Lin, et al.

ONCOLOGY

Clinical

- 869** Diagnostic Performance of ¹²⁴I-Metaiodobenzylguanidine PET/CT in Patients with Pheochromocytoma
Manuel Weber, Jochen Schmitz, Ines Maric, Kim Pabst, Lale Umutlu, Martin Walz, Ken Herrmann, Christoph Rischpler, Frank Weber, Walter Jentzen, et al.
- 875** The Added Value of ⁶⁸Ga-FAPI PET/CT in Patients with Head and Neck Cancer of Unknown Primary with ¹⁸F-FDG-Negative Findings
Bingxin Gu, Xiaoping Xu, Ji Zhang, Xiaomin Ou, Zuguang Xia, Qing Guan, Silong Hu, Zhongyi Yang, and Shaoli Song

- 882 Pretreatment Levels of Soluble Tumor Necrosis Factor Receptor 1 and Hepatocyte Growth Factor Predict Toxicity and Overall Survival After ⁹⁰Y Radioembolization: Potential Novel Application of Biomarkers for Personalized Management of Hepatotoxicity**
Matthew M. Cousins, Theresa P. Devasia, Christopher M. Maurino, Justin Mikell, Matthew J. Schipper, Ravi K. Kaza, Theodore S. Lawrence, Kyle C. Cuneo, and Yuni K. Dewaraja
- 890 Pitfalls and Common Findings in ⁶⁸Ga-FAPI PET: A Pictorial Analysis**
Lukas Kessler, Justin Ferdinandus, Nader Hirmas, Fadi Zarrad, Michael Nader, David Kersting, Manuel Weber, Sandra Kazek, Miriam Sraieb, Rainer Hamacher, et al.
- 897 ■ INVITED PERSPECTIVE. Imaging PD-L1 Expression in Melanoma Brain Metastases**
Sridhar Nimmagadda
- 899 ¹⁸F-BMS986192 PET Imaging of PD-L1 in Metastatic Melanoma Patients with Brain Metastases Treated with Immune Checkpoint Inhibitors: A Pilot Study**
Pieter H. Nienhuis, Inês F. Antunes, Andor W.J.M. Gludemans, Mathilde Jalving, David Leung, Walter Noordzij, Riemer H.J.A. Slart, Erik F.J. de Vries, and Geke A.P. Hospers
- 906 ¹⁸F-FDG PET/CT for Posttreatment Surveillance Imaging of Patients with Stage III Merkel Cell Carcinoma**
Sonia Mahajan, Christopher A. Barker, Audrey Mauguen, Sandra P. D'Angelo, Randy Yeh, and Neeta Pandit-Taskar

Translational

- 912 Combined PARP1-Targeted Nuclear Contrast and Reflectance Contrast Enhance Confocal Microscopic Detection of Basal Cell Carcinoma**
Aditi Sahu, Jose Cordero, Xiancheng Wu, Susanne Kossatz, Ucalene Harris, Paula Demetrio Desouza Franca, Nicholas R. Kurtansky, Niasia Everett, Stephen Dusza, Jilliana Monnier, et al.

AI/ADVANCED IMAGE ANALYSIS

- 919 Effects of Tracer Uptake Time in Non-Small Cell Lung Cancer ¹⁸F-FDG PET Radiomics**
Guilherme D. Kolinger, David Vallez Garca, Gerbrand Maria Kramer, Virginie Frings, Gerben J.C. Zwezerijnen, Egbert F. Smit, Adrianus Johannes de Langen, Irène Buvat, and Ronald Boellaard

NEUROLOGY

Clinical

- 925 Predicting the Outcome of Epilepsy Surgery by Covariance Pattern Analysis of Ictal Perfusion SPECT**
Jila Taherpour, Mariam Jaber, Berthold Voges, Ivayla Apostolova, Thomas Sauvigny, Patrick M. House, Michael Lanz, Matthias Lindenau, Susanne Klutmann, Tobias Martens, et al.
- 931 ■ BRIEF COMMUNICATION. Relationship Between ¹⁸F-Flortaucipir Uptake and Histologic Lesion Types in 4-Repeat Tauopathies**
Keith A. Josephs, Nirubol Tosakulwong, Stephen D. Weigand, Marina Buciu, Val J. Lowe, Dennis W. Dickson, and Jennifer L. Whitwell

Translational

- 936 First-in-Humans Brain PET Imaging of the GluN2B-Containing *N*-methyl-D-aspartate Receptor with (*R*)-¹¹C-Me-NB1**
Lucas Rischka, Chrysoula Vraka, Verena Pichler, Sazan Rasul, Lukas Nics, Gregor Gryglewski, Patricia Handschuh, Matej Murgaš, Godber M. Godbersen, Leo R. Silberbauer, et al.
- 942 Synaptic Vesicle Glycoprotein 2A Is Affected in the Central Nervous System of Mice with Huntington Disease and in the Brain of a Human with Huntington Disease Postmortem**
Daniele Bertoglio, Jeroen Verhaeghe, Leonie Wyffels, Alan Miranda, Sigrid Stroobants, Ladislav Mrzljak, Celia Dominguez, Mette Skinbjerg, Jonathan Bard, Longbin Liu, et al.

CARDIOVASCULAR

Clinical

- 948 ■ BRIEF COMMUNICATION. Feasibility of In Vivo Imaging of Fibroblast Activation Protein in Human Arterial Walls**
Meiqi Wu, Jing Ning, Jingle Li, Zhichao Lai, Ximin Shi, Haiqun Xing, Marcus Hacker, Bao Liu, Li Huo, and Xiang Li

RADIOCHEMISTRY

Basic

- 952 ■ FEATURED BASIC SCIENCE ARTICLE. Albumin Binder-Conjugated Fibroblast Activation Protein Inhibitor Radiopharmaceuticals for Cancer Therapy**
Mengxin Xu, Pu Zhang, Jie Ding, Junyi Chen, Li Huo, and Zhibo Liu

PHYSICS AND INSTRUMENTATION

Clinical

- 959 Feasibility of Acquisitions Using Total-Body PET/CT with an Ultra-Low ¹⁸F-FDG Activity**
Yan Hu, Guobing Liu, Haojun Yu, Ying Wang, Chenwei Li, Hui Tan, Shuguang Chen, Jianying Gu, and Hongcheng Shi

LETTERS TO THE EDITOR

- 966 The Will Rogers Phenomenon and PSMA PET/CT**
Nicholas C. Friedman and Edward Hines, Jr.

DEPARTMENTS

- 10A This Month in JNM**
- 967 Book Review**
Hossein Jadvar